Anticancer effects of Ac-Phe-Lys-PABC-doxorubicin via mitochondria-centered apoptosis involving reactive oxidative stress and the ERK1/2 signaling pathway in MGC-803 cells

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1681-1686

  Zhong, Yan Jun ^a   Liu, Shao Ping ^a   Firestone, Raymond A ^b   Hong, Ya Ping ^b   Li, Yan ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Nanjing Meihua Pharmaceuticals Ltd   (China)

Author keywords

Cathepsin B; Doxorubicin; Gastric cancer; Prodrugs; Targeting therapy

Indexed keywords

CATHEPSIN B; CYTOCHROME C; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OLIGOPEPTIDE; PRODRUG; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; G2 PHASE CELL CYCLE CHECKPOINT; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION SWELLING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CATHEPSIN B; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE SIGNALING SYSTEM; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MITOCHONDRIAL SWELLING; OLIGOPEPTIDES; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; S PHASE CELL CYCLE CHECKPOINTS; SIGNAL TRANSDUCTION;

EID: 84882614622     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2629     Document Type: Article

References (27)

1. Gianni L, Grasselli G, Cresta S, Locatelli A, Viganò L and Minotti G: Anthracyclines. Cancer Chemother Biol Response Modif 21: 29-40, 2003.
2. Abu Ajaj K, Graeser R, Fichtner I and Kratz F: In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer Chemother Pharmacol 64: 413-418, 2009.
3. Kratz F, Warnecke A, Schmid B, Chung DE and Gitzel M: Prodrugs of anthracyclines in cancer chemotherapy. Curr Med Chem 13: 477-523, 2006.
4. Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, et al: Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 34: 1629-1636, 2009.
5. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, et al: Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 20: 1668-1676, 2002.
6. Podgorski I and Sloane BF: Cathepsin B and its role(s) in cancer progression. Biochem Soc Symp 70: 263-276, 2003.
7. Calderón M, Graeser R, Kratz F and Haag R: Development of enzymatically cleavable prodrugs derived from dendritic polyglycerol. Bioorg Med Chem Lett 19: 3725-3728, 2009.
8. Kovár M, Strohalm J, Etrych T, Ulbrich K and Ríhová B: Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect. Bioconjug Chem 13: 206-215, 2002.
9. Thanou M and Duncan R: Polymer-protein and polymer-drug conjugates in cancer therapy. Curr Opin Investig Drugs 4: 701-709, 2003.
10. Mai J, Waisman DM and Sloane BF: Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta 1477: 215-230, 2000.
11. Kratz F, Müller IA, Ryppa C and Warnecke A: Prodrug strategies in anticancer chemotherapy. Chem Med Chem 3: 20-53, 2008.
12. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, et al: Phase I clinical and pharmacokinetic study of PK1 (N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin): first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 5: 83-94, 1999.
13. Dubowchik GM and Firestone RA: Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg Med Chem Lett 8: 3341-3346, 1998.
14. Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K, et al: Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem 13: 855-869, 2002.
15. Dubowchik GM, Mosure K, Knipe JO and Firestone RA: Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett 8: 3347-3352, 1998.
16. Shao LH, Liu SP, Hou JX, Zhang YH, Peng CW, Zhong YJ, et al: Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study. Cancer 118: 2986-2996, 2012.
17. Liu LL, Li QX, Xia L, Li J and Shao L: Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats. Toxicology 231: 81-90, 2007.
18. Hancock JT, Desikan R and Neill SJ: Role of reactive oxygen species in cell signalling pathways. Biochem Soc Trans 29: 345-350, 2001.
19. Fruehauf JP and Meyskens FL Jr: Reactive oxygen species: a breath of life or death? Clin Cancer Res 13: 789-794, 2007.
20. Korsmeyer SJ, Yin XM, Oltvai ZN, Veis-Novack DJ and Linette GP: Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family. Biochim Biophys Acta 1271: 63-66, 1995.
21. Gupta S: Molecular signaling in death receptor and mitochondrial pathways of apoptosis (Review). Int J Oncol 22: 15-20, 2003.
22. Tsang WP, Chau SP, Kong SK, Fung KP and Kwok TT: Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci 73: 2047-2058, 2003.
23. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S and Kalyanaraman B: Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem 279: 25535-25543, 2004.
24. Moungjaroen J, Nimmannit U, Callery PS, Wang L, Azad N, Lipipun V, et al: Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation. J Pharmacol Exp Ther 319: 1062-1069, 2006.
25. Peng CW, Liu XL, Chen C, Liu X, Yang XQ, Pang DW, et al: Patterns of cancer invasion revealed by QDs-based quantitative multiplexed imaging of tumor microenvironment. Biomaterials 32: 2907-2917, 2011.
26. Shinomol GK, Muralidhara: Effect of Centella asiatica leaf powder on oxidative markers in brain regions of prepubertal mice in vivo and its in vitro efficacy to ameliorate 3-NPA-induced oxidative stress in mitochondria. Phytomedicine 15: 971-984, 2008.
27. Kovár L, Strohalm J, Chytil P, Mrkvan T, Kovár M, Hovorka O, et al: The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line. Bioconjug Chem 18: 894-902, 2007